Diagnostics: ABI’s Hunkapiller departs, Burzik in with personal meds

Oct 01, 2004

Premium

The press release announcing the departure of Michael Hunkapiller, longtime face of Applied Biosystems, left more questions than answers. Hunkapiller had “decided to retire, effective immediately,” according to the release, and had headed straight for a two-week vacation in Hawaii where he could not be reached, according to an ABI spokesman.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Aiming for the Mutations

The chief executive of the National Health Service in England is to call for tumor-agnostic drugs to be "fast-tracked," according to the Times.

Why in Decline?

Researchers in Australia are sequencing the Wollemi pine tree to try to protect it from extinction, Australia's ABC News reports.

Time Off and a Connection

Computerworld ranks Illumina as one of the top midsize organizations to work at in IT.

Genome Research Papers Examine Epigenetic Aging and Method to ID CNVs

In Genome Research this week: links between biological aging and mutations affecting epigenetic regulators; long-read sequencing-based strategy to map chromatin accessibility; and more.

Menu